Article
Polymorphisms in the F8 gene and MHC-II variants as risk factors for the development of inhibitory anti-factor VIII antibodies during the treatment of hemophilia a: a computational assessment.
PLoS computational biology - 1 Jan 2013
Pandey Gouri Shankar, Yanover Chen, Howard Tom E, Sauna Zuben E
Abstract excerpt
The development of neutralizing anti-drug-antibodies to the Factor VIII protein-therapeutic is currently the most significant impediment to the effective management of hemophilia A. Common non-synonymous single nucleotide polymorphisms (ns-SNPs) in the F8 gene occur as six haplotypes in the human population (denoted H1 to H6) of which H3 and H4 have been associated with an increased risk of developing anti-drug...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.